TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update

Marianne Vulliemoz*, Stephan Brand, Pascal Juillerat, Christian Mottet, Shomron Ben-Horin, Pierre Michetti

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years. Summary: This review article aimed to provide an update on recent advances in TNF antagonist therapy for IBDs. Key Messages: Their position in the treatment algorithm has evolved to "rapid step-up therapy"or "top-down therapy"according to disease severity and patients' characteristics. Limitations of anti-TNF antagonists include loss of response in up to 30-50% of patients with or without the development of antibodies. Therapeutic drug monitoring should provide a tailored, personalized approach to this scenario. Recently, biosimilar agents have been approved for IBDs and are considered equivalent in efficacy to the originator.

Original languageEnglish
Pages (from-to)16-26
Number of pages11
JournalDigestion
Volume101
Issue numberSuppl1
DOIs
StatePublished - 1 Sep 2020
Externally publishedYes

Keywords

  • Biologicals
  • Crohn's disease
  • Inflammatory bowel diseases
  • Infliximab
  • TNF inhibitors
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update'. Together they form a unique fingerprint.

Cite this